This is a routine governance filing with no immediate trading implications. Monitor for any future executive departures or change-of-control events that would trigger the severance provisions, but no catalyst is present today.
AXSM drugs
AXSM drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 10 $246.34entry
- T+1 · 5mo ago +3.02%α +1.32% · $253.77
- T+5 · 5mo ago +2.26%α −1.17% · $251.91
- T+20 · 4mo ago +1.06%α −2.56% · $248.95
- T+60 · 2mo ago −15.42%α −22.00% · $208.35
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Axsome Therapeutics adopted a formal Executive Severance and Change in Control Plan effective June 5, 2026, covering the CEO (Tier 1), other Section 16 officers (Tier 2), and VPs+ (Tier 3). The plan provides cash severance of 18/12/6 months' base salary outside a change of control, and 24/18/9 months' salary plus target bonus, full equity acceleration, and COBRA payments upon a qualifying termination during a change of control period. This is a routine adoption of a standardized severance framework that supersedes prior individual agreements, with no departure or appointment of any officer.
Key Facts
- Plan adopted June 5, 2026, approved by Compensation Committee
- CEO (Tier 1) gets 18 months base salary severance outside CIC, 24 months plus target bonus and full equity vesting during CIC period
- Other Section 16 officers (Tier 2) get 12 months base salary outside CIC, 18 months plus target bonus and full equity vesting during CIC period
- VPs+ (Tier 3) get 6 months base salary outside CIC, 9 months plus target bonus and full equity vesting during CIC period
- Plan supersedes all prior severance arrangements in employment agreements
- No officer departures or appointments were announced
Financial Impact
No specific dollar amounts disclosed; severance is formula-based on base salary and target bonus. The plan is unfunded and paid from general assets.
Risk Factors
- No material risks identified from this filing alone
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-264047 |
| Document: axsm-20260605.htm | 0001193125-26-264047 |
| Document: 0001193125-26-264047-index-headers.html | 0001193125-26-264047 |
| Document: 0001193125-26-264047-index.html | 0001193125-26-264047 |
| Document: 0001193125-26-264047.txt | 0001193125-26-264047 |
Track record
26 reports on AXSM
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
- Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
- Aug 10, 202614w ago 8-K Neutral 6/10 No price data
- Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
- Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
- Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
- Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
- Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers